From: JEnglish@technip.com
Sent: Friday, June 04, 2004 4:55 PM
To: HENIGA@cder.fda.gov
Cc: fdadockets@oc.fda.gov; SaOstrove@technip.com
Subject: Re: Part 11 meeting - Docket number 2004N-0133 - Replacement
and Final transmittal





Anne:

Please find attached the text of my presentation and the powerpoint slides.
Please note this pdf has been changed and replaces the first transmittal
This is the requested presentation as per you e-mail and confirmation
letter dated 25 MAY 2004.

(See attached file: JEnglish_FDAPart11_Docket2004N-1033.pdf)(See attached
file: JEnglish_FDAPart11_Docket 2004N-0133.ppt)

Please advise if there are any problems opening it, or with the choice of
format.  As a precaution, since I will be away from e-mail until Monday
evening, you should cc: Dr Steve Ostrove with any issues.  (He is included
on this email as well.  His internet address is SAOstrove@technip.com)

Best regards,

John English, Principal Validation Consultant
TECHNIP BioPharm Inc.
106 Allen Road, Suite 300 - Rm 3261
Liberty Corner, NJ 07938 - USA
Tel:  +1.908.604.7552
Fax: +1.908.604.7501
Cell:+1.973.727.5679
E-mail:  jenglish@technip.com
Technip BioPharm (In Progress):  http://www.technipbiopharm.com
Technip Life Sciences Page:
http://www.technip.com/english/experience/life.htm